Showing results (91-100 of 127) with videos related to
Sort By:
Pageof 13
Journal for Immunotherapy of Cancer|November 17, 2024
Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumorsDiwakar Davar, Benedito A Carneiro, Grace K Dy, et al.Journal for Immunotherapy of Cancer|August 3, 2024
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)Diwakar Davar, Ludimila Cavalcante, Nehal Lakhani, et al.Oncotarget|July 25, 2022
Predicting cancer immunotherapy response from gut microbiomes using machine learning modelsHai Liang, Jay-Hyun Jo, Zhiwei Zhang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2018
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced MelanomaDiwakar Davar, Hong Wang, Joe-Marc Chauvin, et al.Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Mitochondrial Imaging Detects Early Cardiac Responses to Cancer ImmunotherapyHee-Don Chae, Uttam Shrestha, Millie Das, et al.Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanomaLilit Karapetyan, Anthony R Cillo, Shuaichao Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2025
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell CarcinomaDan P Zandberg, Jacob B Allred, Ari J Rosenberg, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2026
Mitochondrial Imaging Detects Early Cardiac Changes Following Cancer ImmunotherapyHee-Don Chae, Uttam Shrestha, Millie Das, et al.Medrxiv : the Preprint Server for Health Sciences|May 7, 2024
Radiomic analysis of patient and inter-organ heterogeneity in response to immunotherapies and BRAF targeted therapy in metastatic melanomaAlexandra Tompkins, Zane N Gray, Rebekah E Dadey, et al.Cancer|August 3, 2025
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b studyMohammed M Milhem, Yousef Zakharia, Diwakar Davar, et al.Pageof 13